That was one hell of an R&D Spotlight episode published this week by Avacta #AVCT. A must-watch for holders. I thought I’d provide a recap of the investment case on here, as the Company sits on the cusp of a major news period that could prove transformational. The pre | CISION

We are thrilled to announce our two new additions to the Avacta pipeline. Our pre|CISION peptide drug conjugate technology can be implemented in multiple options. More to come soon. Stay tuned #AVCT #LetsDoThis #PeptidesCreateHope

A mention for #AVCT as a 'key takeaway' in a new ADC market report from Delve Insight - a consulting firm that lists GSK, Merck, J&J, Abbvie, Gilead, Takeda, Daiichi and others as clients finance.yahoo.com/news/global-an…

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona. avacta.com/avacta-reports… #AVCT

The evolution of preCISION is being unveiled today in Barcelona. We believe the future of cancer therapy means not having to choose between eliminating the disease and safeguarding patient wellness. We believe in hope without compromise. #PeptidesCreateHope #LetsDoThis #AVCT

Countries as twins animated by artificial intelligence ...

#ONDO announces new contract with Selective Insurance 🤝 🇺🇸 Expanding into 4 new states 📍 Launching in Virginia, Pennsylvania, Indiana, & Ohio 🚰 Growing confidence & momentum among U.S. insurers in the #LeakBot solution Read more below 👇 londonstockexchange.com/news-article/O…

Raleigh Williams Dane- Chemo such as doxorubicin is actually an incredibly powerful drug that is highly effective at fighting cancer. The problem with it, is that it is given intravenously so it attacks healthy and cancerous cells at the same rate causing ghastly side effects. Also, the amount of the

A reminder that we are presenting three posters at the AACR Annual Meeting, two on Monday and one on Tuesday. Stay tuned for further info and a link to the posters when they go live. #AVCT

Christina Coughlin Avacta #LetsCommercialiseIt #avct

FAP is THE perfect target to leverage bystander killing due to its proximity to cancer cells and colocalisation with tumour vasculature (TNBC, NSCLC, PDAC and CRC) #AACR25 $TEM #AVCT tech capitalises on this by releasing the payload into the TME’s extracellular space

✈️ Back to the USA next week — state-hopping to meet with C-level execs from some of the biggest insurers in the game. Looking forward to great conversations about prevention, claims savings, and scaling LeakBot across the States. Let’s go! 🇺🇸💧 #ONDO #LeakBot #Insurtech

Citi downgrades $MRK on #Keytruda patent cliff. Brokerage raises concerns about MRK's blockbuster cancer therapy Keytruda losing exclusivity. "MRK could benefit from making a large acquisition (over $10 billion) to offset the decline in Keytruda sales, says brokerage" #AVCT

Read the new Citeline article, 'The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective', here: insights.citeline.com/in-vivo/innova… #AVCT

#AVCT’s AVA6103 seeks to harness exatecan. 🧬 Exatecan is an extremely potent topoisomerase I inhibitor (why the CEO nicknames AVA6103 ‘the beast’) that shows extreme promise in cancer treatment, but its clinical use has been limited. Doxorubicin is a Top 2 inhibitor. It blocks

"90% of all solid tumors express FAP." And we know that solid tumors account for~90% of cancer cases (with the remaining 10% mostly made up of blood cancers - leukemias, lymphomas, multiple myeloma). Accordingly, #AVCT is in effect stating that its pre|CISION delivery platform

Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress. avacta.com/avacta-to-pres… #AVCT

#AVCT An antibody drug conjugate (ADC) is comprised of: 🧬 Antibody 🖇️ Linker (a chemical bridge which links the drug to the antibody) 🧪 Drug (referred to as Toxin/Payload/Warhead)

Looking forward to October in Germany - cue up the data from the FAP-Dox dose escalation trial, including the longer term follow up data. Key data for the pre|CISION platform #AVCT Silent in the bloodstream. Active in the tumor.